TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Polyrizon Ltd. ( (PLRZ) ) is now available.
On September 19, 2025, Polyrizon Ltd. announced the submission of its pre-submission package to the FDA for its PL-14 Allergy Blocker, a novel nasal spray designed to provide relief from allergic rhinitis symptoms. This submission marks a significant step in Polyrizon’s regulatory strategy, potentially paving the way for marketing clearance and addressing unmet needs in allergy treatment. The PL-14 Allergy Blocker aims to offer rapid, long-lasting relief by blocking allergen entry, positioning Polyrizon for accelerated development in the allergy treatment market.
More about Polyrizon Ltd.
Polyrizon Ltd. is a biotechnology company that specializes in developing innovative medical device hydrogels delivered as nasal sprays. Their primary focus is on creating products that form a protective barrier in the nasal cavity to prevent viruses and allergens from contacting nasal tissues. The company is also working on technologies for the intranasal delivery of drugs and active pharmaceutical ingredients.
Average Trading Volume: 6,129,915
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.11M
For an in-depth examination of PLRZ stock, go to TipRanks’ Overview page.